ISRCTN17754650进行中（未招募）未知
STOP - Successful Treatment of Paranoia: Replacing harmful paranoid thoughts with better alternatives
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 274
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current participant inclusion criteria as of 24/08/2022:
- •1. Any clinical diagnosis featuring clinically significant persecutory or paranoid symptoms, present for at least the preceding month. This will be operationalised as a score of 3 (mild”) or more on the paranoia item (item 6) of the Positive and Negative Syndrome Scale (PANSS).
- •2. Displaying an interpretation bias =2 on the 8-item screening version of the Similarity Ratings Task (SRT). The screening score has a range of +3 (strong positive bias) to -3 (strong paranoid bias).
- •3. If on psychotropic medication, then stable on medication for at least the last 3 months and expected to be so for the study duration
- •4. Aged =18 years
- •5. Capacity to consent
- •Previous participant inclusion criteria:
- •1. Any clinical diagnosis featuring clinically significant persecutory or paranoid symptoms, present for at least the preceding month
- •2. Showing paranoid symptoms >/=3 on the paranoia item (item 6) of the Positive and Negative Symptoms Scale (PANSS)
- •3. Displaying an interpretation bias >/= 1 on the 8-item screening version of the Similarity Ratings Task (SRT). The screening score has a range of +3 (strong positive bias) to -3 (strong paranoid bias)
- •4. If on psychotropic medication, then stable on medication for at least the last 3 months and expected to be so for the study duration
- •5. Age 18 - 65 years
- •6. Capacity to consent, assessed by clinician using the South London and Maudsley NHS Trust required standard protocol
排除标准
- •Current participant exclusion criteria as of 24/08/2022:
- •1. Severe cognitive impairment
- •2. Illiteracy or inability to understand written and spoken English for any other reason
- •3. Major physical illness (cancer, heart disease, stroke)
- •4. Major substance or alcohol misuse, assessed by the SCID-V screen
- •5. Currently receiving, or soon due to receive, a psychological intervention targeting the same psychological mechanism as STOP (i.e., paranoid belief change) or having done so in the last 3 months
- •6. Currently taking part in any other interventional research study
- •7. Scoring 7 (defined as ‘Extreme’) on item 6 of the PANSS
- •8. At high risk of suicide as indicated by the Columbia Suicide Severity Rating Scale (C-SSRS) -Screen Version
- •Previous participant exclusion criteria:
- •1. Severe cognitive impairment
- •2. Illiteracy
- •3. Major physical illness (cancer, heart disease, stroke)
- •4. Major substance or alcohol misuse, assessed by the SCID-V screen
- •5. Currently receiving, or soon due to receive, a psychological intervention targeting the same psychological mechanism as CBM-pa (paranoid beliefs) or having done so in the last 3 months
研究者
相似试验
已完成
不适用
Inference Based Approach, treatment for paranoia * A replicated randomized single-case A-B-phase desigParanoiasuspicion10039628NL-OMON52536GGZ Centraal (Amersfoort)6
招募中
不适用
Alternative therapies for the control of anxiety and discomfort after wisdom molar extractioMolar, ThirdEdemaTrismusPainA14.549.167.860.525.500F01.470.132RBR-6kcxvrcDepartamento de Estomatologia da Universidade Federal do Paraná
已完成
2 期
De-escalation and stopping treatment of imatinib, nilotinib or sprycel in chronic myeloid leukaemiaTopic: National Cancer Research NetworkSubtopic: Haematological OncologyDisease: Leukaemia (chronic)Chronic myelogenous leukaemiaCancerISRCTN74084226niversity of Liverpool (UK)168
进行中（未招募）
1 期
A trial of de-escalation and stopping treatment in chronic myeloid leukaemia patients with excellent responses to tyrosine kinase inhibitor therapy DESTINY (De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in chronic myeloid leukaemia)Chronic myeloid leukaemiaMedDRA version: 16.0 Level: LLT Classification code 10009015 Term: Chronic myeloid leukemia System Organ Class: 100000004864MedDRA version: 16.0 Level: LLT Classification code 10009016 Term: Chronic myeloid leukemia in remission System Organ Class: 100000004864EUCTR2012-004025-24-GBniversity of Liverpool174
已完成
不适用
Mentalization-Based Treatment for Psychosis: a randomized controlled trial for outpatients with a nonaffective psychotic disorder.Non-affective psychotic disorders10039628NL-OMON44966Academisch Medisch Centrum90